KINIKSA PHARMACEUTICALS LTD's ticker is KNSA and the CUSIP is G5269C101. A total of 95 filers reported holding KINIKSA PHARMACEUTICALS LTD in Q2 2022. The put-call ratio across all filers is 0.44 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $1,140 | +23.4% | 65,607 | -0.1% | 0.48% | +30.4% |
Q2 2023 | $924 | +39.4% | 65,654 | +6.6% | 0.37% | +32.7% |
Q1 2023 | $663 | -28.2% | 61,599 | -0.0% | 0.28% | -32.2% |
Q4 2022 | $923 | -99.9% | 61,609 | -24.9% | 0.41% | +37.6% |
Q1 2022 | $815,000 | -10.1% | 81,995 | +6.4% | 0.30% | -8.0% |
Q4 2021 | $907,000 | – | 77,069 | – | 0.32% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Spearhead Capital Advisors, LLC | 202,580 | $2,601,000 | 2.82% |
Lion Point Capital, LP | 480,000 | $5,140,000 | 1.13% |
HHLR ADVISORS, LTD. | 2,920,023 | $37,493,000 | 0.99% |
TANG CAPITAL MANAGEMENT LLC | 600,000 | $7,704,000 | 0.94% |
Rubric Capital Management LP | 1,446,107 | $18,568,000 | 0.94% |
AlphaCentric Advisors LLC | 43,000 | $552,000 | 0.57% |
RICE HALL JAMES & ASSOCIATES, LLC | 749,933 | $9,629,000 | 0.56% |
Parkman Healthcare Partners LLC | 126,192 | $1,620,000 | 0.46% |
Birchview Capital, LP | 30,000 | $385,000 | 0.27% |
Baker Brothers Advisors | 2,799,577 | $35,947,000 | 0.24% |